JP2016504290A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504290A5
JP2016504290A5 JP2015544124A JP2015544124A JP2016504290A5 JP 2016504290 A5 JP2016504290 A5 JP 2016504290A5 JP 2015544124 A JP2015544124 A JP 2015544124A JP 2015544124 A JP2015544124 A JP 2015544124A JP 2016504290 A5 JP2016504290 A5 JP 2016504290A5
Authority
JP
Japan
Prior art keywords
diamine
fluoro
benzimidazol
pyrimidine
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015544124A
Other languages
English (en)
Japanese (ja)
Other versions
JP6412503B2 (ja
JP2016504290A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/071132 external-priority patent/WO2014081906A2/en
Publication of JP2016504290A publication Critical patent/JP2016504290A/ja
Publication of JP2016504290A5 publication Critical patent/JP2016504290A5/ja
Application granted granted Critical
Publication of JP6412503B2 publication Critical patent/JP6412503B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015544124A 2012-11-21 2013-11-21 置換逆ピリミジンBmi−1阻害剤 Active JP6412503B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21
US61/728,907 2012-11-21
PCT/US2013/071132 WO2014081906A2 (en) 2012-11-21 2013-11-21 Substituted reverse pyrimidine bmi-1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018183173A Division JP6617186B2 (ja) 2012-11-21 2018-09-28 置換逆ピリミジンBmi−1阻害剤

Publications (3)

Publication Number Publication Date
JP2016504290A JP2016504290A (ja) 2016-02-12
JP2016504290A5 true JP2016504290A5 (enExample) 2017-01-05
JP6412503B2 JP6412503B2 (ja) 2018-10-24

Family

ID=50776672

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015544124A Active JP6412503B2 (ja) 2012-11-21 2013-11-21 置換逆ピリミジンBmi−1阻害剤
JP2018183173A Active JP6617186B2 (ja) 2012-11-21 2018-09-28 置換逆ピリミジンBmi−1阻害剤
JP2019203706A Active JP6918898B2 (ja) 2012-11-21 2019-11-11 置換逆ピリミジンBmi−1阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018183173A Active JP6617186B2 (ja) 2012-11-21 2018-09-28 置換逆ピリミジンBmi−1阻害剤
JP2019203706A Active JP6918898B2 (ja) 2012-11-21 2019-11-11 置換逆ピリミジンBmi−1阻害剤

Country Status (32)

Country Link
US (3) US10428050B2 (enExample)
EP (1) EP2922828B1 (enExample)
JP (3) JP6412503B2 (enExample)
KR (4) KR20220143164A (enExample)
CN (2) CN104918919A (enExample)
AR (1) AR093579A1 (enExample)
AU (1) AU2013348009C1 (enExample)
BR (1) BR112015011760B1 (enExample)
CA (1) CA2892045C (enExample)
CL (1) CL2015001377A1 (enExample)
CR (1) CR20150294A (enExample)
CU (1) CU24387B1 (enExample)
DK (1) DK2922828T3 (enExample)
EA (2) EA035349B1 (enExample)
EC (1) ECSP15019948A (enExample)
ES (1) ES2821529T3 (enExample)
HK (1) HK1215032A1 (enExample)
IL (2) IL238871B (enExample)
MA (1) MA38208B1 (enExample)
MX (2) MX385385B (enExample)
NI (1) NI201500072A (enExample)
NZ (2) NZ746607A (enExample)
PE (1) PE20151413A1 (enExample)
PH (1) PH12015501130B1 (enExample)
PL (1) PL2922828T3 (enExample)
PT (1) PT2922828T (enExample)
SA (1) SA517381847B1 (enExample)
SG (2) SG11201503982XA (enExample)
TW (1) TWI623531B (enExample)
UA (1) UA118094C2 (enExample)
WO (1) WO2014081906A2 (enExample)
ZA (1) ZA201503642B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220143164A (ko) * 2012-11-21 2022-10-24 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 bmi-1 저해제
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
JP6529492B2 (ja) * 2013-07-11 2019-06-12 アジオス ファーマシューティカルズ, インコーポレイテッド 癌の処置のためのidh2突然変異体阻害剤としての2,4−または4,6−ジアミノピリミジン化合物
AU2013399092A1 (en) 2013-08-30 2016-03-17 Ptc Therapeutics, Inc. Substituted pyrimidine Bmi-1 inhibitors
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
US10874355B2 (en) 2014-04-24 2020-12-29 Cognoa, Inc. Methods and apparatus to determine developmental progress with artificial intelligence and user input
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
EP3402780A1 (en) * 2016-01-14 2018-11-21 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
EP3539033B1 (en) 2016-11-14 2024-10-02 Cognoa, Inc. Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability
JP7324709B2 (ja) 2017-02-09 2023-08-10 コグノア,インク. デジタル個別化医療のためのプラットフォームとシステム
WO2019028171A1 (en) 2017-08-01 2019-02-07 Ptc Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
MX2021001870A (es) * 2018-08-17 2021-07-15 Ptc Therapeutics Inc Metodo para tratar cancer pancreatico.
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
WO2020150326A1 (en) 2019-01-15 2020-07-23 Ptc Therapeutics, Inc. Method for treating an acute myeloid leukemia
MX2021010398A (es) * 2019-02-28 2022-01-18 Ptc Therapeutics Inc Metodo para tratar un mieloma multiple.
KR20210151061A (ko) 2019-03-11 2021-12-13 피티씨 테라퓨틱스, 인크. 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형
KR102643554B1 (ko) 2019-03-22 2024-03-04 코그노아, 인크. 개인 맞춤식 디지털 치료 방법 및 디바이스
WO2020198705A1 (en) * 2019-03-27 2020-10-01 Ptc Therapeutics, Inc. Combinations useful in a method for treating sarcoma
CA3135929A1 (en) * 2019-04-02 2020-10-08 Hinova Pharmaceuticals Inc. Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators
TWI843989B (zh) 2021-02-19 2024-06-01 美商美威高能離子醫療系統公司 用於粒子治療系統之支架
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (enExample) * 1973-09-20 1977-11-30 Delalande Sa
US5750531A (en) 1994-08-13 1998-05-12 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
IN188411B (enExample) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6498165B1 (en) 1999-06-30 2002-12-24 Merck & Co., Inc. Src kinase inhibitor compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
DE60024480T2 (de) 1999-10-27 2006-07-27 Novartis Ag Thiazol und imidazo[4,5-b]pyridin verbindungen und ihre verwendung als pharmazeutika
CN1429222A (zh) 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
CA2401748A1 (en) 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
MXPA03002297A (es) 2000-09-15 2003-06-06 Vertex Pharma Compuestos de triazol utiles como inhibidores de proteina cinasa.
WO2002024681A2 (en) 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
AU2002228922A1 (en) * 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
AU2002239348A1 (en) 2000-12-15 2002-06-24 Glaxo Group Limited Pyrazolopyridine derivatives
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
ES2316546T3 (es) 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
US20030165873A1 (en) * 2001-03-02 2003-09-04 Come Jon H. Three hybrid assay system
WO2003000682A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
JP4342937B2 (ja) 2001-07-03 2009-10-14 バーテックス ファーマシューティカルズ インコーポレイテッド SrcおよびLckタンパク質キナーゼの阻害剤としてのイソキサゾールピリミジン
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003075828A2 (en) 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
NZ537156A (en) 2002-05-23 2007-06-29 Cytopia Pty Ltd Kinase inhibitors
US7494997B2 (en) 2002-06-28 2009-02-24 Nippon Shinyaku Co., Ltd. Amide derivative
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (en) * 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
US7582630B2 (en) 2002-10-15 2009-09-01 Smithkline Beecham Corporation Pyradazine compounds as GSK-3 inhibitors
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
KR101164541B1 (ko) 2004-01-12 2012-07-10 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 선택적 키나제 저해제
JP2007520558A (ja) 2004-02-04 2007-07-26 スミスクライン・ビーチャム・コーポレイション キナーゼ阻害剤として有用なピリミジノン化合物
EP1730146B1 (en) * 2004-03-30 2011-05-04 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
AU2006219231B2 (en) 2005-02-28 2010-01-14 Japan Tobacco Inc. Novel aminopyridine compound with Syk inhibitory activity
PE20061067A1 (es) 2005-03-10 2006-11-30 Bayer Pharmaceuticals Corp Derivados de pirimidina
RU2009101911A (ru) 2006-06-22 2010-07-27 Биовитрум Аб (Пабл) (Se) Производные пиридина и пиразина в качестве ингибиторов mnk-киназы
CN101516873A (zh) 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
EP2074113A1 (en) * 2006-10-03 2009-07-01 NeuroSearch A/S Indazolyl derivatives useful as potassium channel modulating agents
CA2666624C (en) 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
KR20090091306A (ko) 2006-12-22 2009-08-27 노파르티스 아게 암, 염증 및 바이러스 감염 치료용 cdk 억제제로서의 헤테로아릴-헤테로아릴 화합물
AR065015A1 (es) 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Adおよび関連状態の治療のためのピペラジン誘導体
WO2008132502A1 (en) 2007-04-25 2008-11-06 Astrazeneca Ab Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
JP5480813B2 (ja) 2007-11-16 2014-04-23 インサイト・コーポレイション Janusキナーゼ阻害剤としての置換複素環
AU2008333136B2 (en) 2007-12-07 2012-05-10 Astex Therapeutics Ltd Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
AU2009238590A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
ES2605815T3 (es) * 2008-07-01 2017-03-16 Ptc Therapeutics, Inc. Moduladores de la expresión de la proteína Bmi-1
EP2328890B1 (en) 2008-08-06 2012-01-25 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
WO2010026087A1 (en) * 2008-09-02 2010-03-11 Neurosearch A/S Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
WO2010061903A1 (ja) * 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
US20120165309A1 (en) 2009-02-12 2012-06-28 Astellas Pharma Inc. Hetero ring derivative
EP2411387B1 (en) 2009-03-27 2015-08-19 VetDC, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
ES2453097T3 (es) 2009-05-27 2014-04-04 Abbvie Inc. Inhibidores de pirimidina de actividad quinasa
TW201102387A (en) 2009-06-08 2011-01-16 Medicinova Inc Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
CN104151312B (zh) * 2009-06-17 2016-06-15 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
EP2532659A1 (en) 2009-07-07 2012-12-12 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
JP2012533553A (ja) 2009-07-15 2012-12-27 アボット・ラボラトリーズ ピロロピリジン系キナーゼ阻害薬
JP2012533551A (ja) 2009-07-15 2012-12-27 アボット・ラボラトリーズ ピロロピラジン系キナーゼ阻害薬
JP2011136925A (ja) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
AR079993A1 (es) 2010-01-12 2012-03-07 Ab Science Derivados de azol, composiciones farmaceuticas y sus usos para tratar trastornos mediados por una sobreactividad de quinasas
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
JP5905006B2 (ja) * 2010-08-19 2016-04-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 体細胞の人工リプログラミング神経幹細胞(irNSC)への変換
PT2616465E (pt) 2010-09-13 2016-03-09 Novartis Ag Triazino-oxadiazoles
WO2012050884A2 (en) * 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
EP2796456A1 (en) 2010-12-09 2014-10-29 Amgen Inc. Bicyclic compounds as Pim inhibitors
JP5980236B2 (ja) 2011-02-25 2016-08-31 ユーハン・コーポレイションYUHAN Corporation ジアミノピリミジン誘導体及びその製造方法
ES2698847T3 (es) * 2011-07-07 2019-02-06 Merck Patent Gmbh Azaheterociclos sustituidos para el tratamiento del cáncer
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
KR20220143164A (ko) * 2012-11-21 2022-10-24 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 bmi-1 저해제
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
KR20210151061A (ko) * 2019-03-11 2021-12-13 피티씨 테라퓨틱스, 인크. 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형

Similar Documents

Publication Publication Date Title
JP2016504290A5 (enExample)
JP2016529292A5 (enExample)
US11135201B2 (en) Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
JP6728321B2 (ja) 置換ピリミジンBmi−1阻害剤
US10421761B2 (en) Compounds for kinase modulation, and indications therefor
DK2935248T3 (en) RELATIONS AND PROCEDURE FOR CHINESE MODULATION AND INDICATIONS THEREOF
US9771369B2 (en) Compounds and methods for kinase modulation, and indications therefor
JP5815558B2 (ja) キナーゼ調節のための化合物及び方法ならびにそれらの適応症
JP2015511224A5 (enExample)
JP2025134754A (ja) Egfr変異を有するがんを処置するためのアミノ置換ヘテロ環類
RU2020112759A (ru) Гетероциклические соединения в качестве ингибиторов PAD
JP2015517988A5 (enExample)
NZ607060A (en) Substituted imidazoquinoline derivatives as kinase inhibitors
JP2014526526A5 (enExample)
US10925880B2 (en) Combination of PI3K-inhibitors
WO2018195471A1 (en) Syk inhibitors in combination with hypomethylating agents
JP2024529485A (ja) イミダゾ[1,2-b]ピリダジニル化合物及びその使用